Medical management of Crohn’s disease

[1]  P. Rutgeerts,et al.  A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease , 2012, The American Journal of Gastroenterology.

[2]  A. Ananthakrishnan,et al.  Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis , 2012, Digestive Diseases and Sciences.

[3]  W. El-Matary,et al.  Systematic review: the role of tacrolimus in the management of Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[4]  P. Moayyedi,et al.  Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[5]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[6]  D. Porter,et al.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  J. Rhodes,et al.  The role of bacteria in the pathogenesis of inflammatory bowel disease. , 2010, Gut and liver.

[8]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[9]  W. Blonski,et al.  What is the optimal therapy for Crohn’s disease: step-up or top-down? , 2010, Expert review of gastroenterology & hepatology.

[10]  C. McCollough,et al.  Assessment of appropriateness of indications for CT enterography in younger patients , 2010, Inflammatory bowel diseases.

[11]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[12]  S. Hanauer,et al.  Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis , 2009, The American Journal of Gastroenterology.

[13]  Joel G Fletcher,et al.  Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. , 2009, AJR. American journal of roentgenology.

[14]  J. A. Leighton,et al.  Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus , 2009, Endoscopy.

[15]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[16]  S. Reu,et al.  p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. , 2009, Gastroenterology.

[17]  L. Peyrin-Biroulet,et al.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  K. Honey.  The comeback kid: TYSABRI now FDA approved for Crohn disease. , 2008, The Journal of clinical investigation.

[19]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[20]  J. Rosh,et al.  Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. , 2007, Journal of pediatric gastroenterology and nutrition.

[21]  Mark Avigan,et al.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. , 2007, Journal of pediatric gastroenterology and nutrition.

[22]  S. Nikfar,et al.  A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. , 2006, Clinical therapeutics.

[23]  H. Drummond,et al.  The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohort , 2006, Alimentary pharmacology & therapeutics.

[24]  M. Campieri,et al.  Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo‐controlled trial with rifaximin , 2006, Alimentary pharmacology & therapeutics.

[25]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[26]  G. Greenberg,et al.  Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials , 2005, The American Journal of Gastroenterology.

[27]  C. Brensinger,et al.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.

[28]  P. Rutgeerts,et al.  Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. , 2005, Gastroenterology.

[29]  D. Felsenberg,et al.  Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  S. Hanauer,et al.  Crohn’s Is Not a 6-Week Disease: Lifelong Management of Mild to Moderate Crohn’s Disease , 2004, Inflammatory bowel diseases.

[31]  S. Hanauer,et al.  Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  T. Yednock,et al.  Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin , 2003, American Journal of Gastroenterology.

[33]  J. Dahlerup,et al.  Thiopurine methyltransferase genotype distribution in patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[34]  J. Mate,et al.  Hepatosplenic T-Gammadelta Lymphoma in a Patient with Crohn's Disease Treated with Azathioprine , 2003, Leukemia & lymphoma.

[35]  C. Moskaluk,et al.  Down-Regulation of Intestinal Lymphocyte Activation and Th1 Cytokine Production by Antibiotic Therapy in a Murine Model of Crohn’s Disease1 , 2002, The Journal of Immunology.

[36]  A. Zinsmeister,et al.  The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. , 2002, Gastroenterology.

[37]  R. Weinshilboum,et al.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide , 2001, Gut.

[38]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[39]  P. Rutgeerts.  The use of budesonide in the treatment of active Crohn's disease is good clinical practice. , 2001, Inflammatory bowel diseases.

[40]  P. Savelkoul,et al.  The Bacterial Flora in Inflammatory Bowel Disease: Current Insights in Pathogenesis and the Influence of Antibiotics and Probiotics , 2001, Scandinavian journal of gastroenterology. Supplement.

[41]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[42]  M. Campieri,et al.  Oral budesonide is as effective as oral prednisolone in active Crohn’s disease , 1997, Gut.

[43]  Peppercom Ma.  6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. , 1996 .

[44]  P. Rutgeerts,et al.  Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.

[45]  D. Jewell,et al.  A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.

[46]  M. Kamm,et al.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.

[47]  J. Esdaile,et al.  Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. , 1993, Arthritis and rheumatism.

[48]  P. Vacek,et al.  Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. , 1990, The Journal of rheumatology.

[49]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[50]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[51]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[52]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.